The Experimental Quest for Longevity: Rapamycin’s Rising Popularity
March 15, 2024
At 77, David Sandler from Bergen County, N.J., has ventured into an experimental approach to longevity by starting a regimen of rapamycin, a drug with a growing yet unproven reputation for extending life. Initially approved for transplant patients, rapamycin has caught the attention of the longevity community, including celebrity doctors and researchers, due to its potential to slow aging processes based on animal studies. Despite the lack of FDA approval for aging treatment and the unknowns regarding optimal dosing and side effects, rapamycin is being marketed and used off-label for anti-aging purposes. Enthusiasts, driven by promising animal research and anecdotal evidence, are eager to incorporate rapamycin into their health routines. They hope to tap into its speculated benefits for extending life span and improving health quality. However, the scientific community remains divided, underscoring the need for more research to establish the safety and efficacy of rapamycin as a longevity drug.
To read more, click here.
[Source: The Washington Post, March 15th, 2024]
